Han J H, Tollefsen D M
Division of Hematology, Department of Internal Medicine, Washington University, St. Louis, Missouri 63110, USA.
Biochemistry. 1998 Mar 3;37(9):3203-9. doi: 10.1021/bi9722195.
Heparin cofactor II (HCII) inhibits thrombin rapidly in the presence of heparin or dermatan sulfate. The product of the inhibition reaction is a kinetically stable, 1:1 complex between the two proteins. We recently observed that heparin induces dissociation of complexes containing thrombin and the reactive site mutant HCII(L444R) to yield active thrombin and cleaved inhibitor (Han, J. -H., Van Deerlin, V. M. D., and Tollefsen, D. M. (1997) J. Biol. Chem. 272, 8243-8249). In the current study, we have investigated the mechanism by which heparin induces dissociation of the thrombin-HCII(L444R) complex. Heparin oligosaccharides >/=6 sugars in length induce dissociation, which suggests that dissociation does not depend on binding of a heparin molecule simultaneously to both proteins in the complex. Binding of heparin to HCII(L444R) in the complex also does not appear to be required, since the heparin dose response is unaltered for complexes containing the double mutant HCII(L444R/K173Q), which has decreased affinity for heparin. By contrast, binding of heparin to thrombin appears to be necessary and sufficient to induce dissociation. First, heparin fails to induce dissociation of complexes that contain thrombin(K236E), a variant with decreased heparin affinity. Second, a monoclonal IgG that interacts with the heparin-binding site of thrombin mimicks heparin in its ability to induce dissociation of the thrombin-HCII(L444R) complex. Finally, the complex of HCII(L444R) with thrombin(desPPW), which binds normally to heparin but lacks Pro60BPro60CTrp60D in an insertion loop ("60-loop") between the heparin-binding site and the catalytic site, does not dissociate in the presence of heparin. These results suggest that binding of heparin to thrombin induces an allosteric effect causing destabilization of the thrombin-HCII(L444R) complex and that the allosteric effect may be mediated by the 60-loop.
肝素辅因子II(HCII)在肝素或硫酸皮肤素存在的情况下能迅速抑制凝血酶。抑制反应的产物是这两种蛋白质之间动力学稳定的1:1复合物。我们最近观察到,肝素能诱导含有凝血酶和活性位点突变体HCII(L444R)的复合物解离,产生活性凝血酶和裂解的抑制剂(Han,J. -H.,Van Deerlin,V. M. D.,和Tollefsen,D. M.(1997)J. Biol. Chem. 272,8243 - 8249)。在当前的研究中,我们研究了肝素诱导凝血酶 - HCII(L444R)复合物解离的机制。长度≥6个糖残基的肝素寡糖可诱导解离,这表明解离并不依赖于肝素分子同时与复合物中的两种蛋白质结合。复合物中肝素与HCII(L444R)的结合似乎也不是必需的,因为对于含有对肝素亲和力降低的双突变体HCII(L444R/K173Q)的复合物,肝素剂量反应没有改变。相比之下,肝素与凝血酶的结合似乎是诱导解离所必需且充分的。首先,肝素不能诱导含有肝素亲和力降低的变体凝血酶(K236E)的复合物解离。其次,一种与凝血酶的肝素结合位点相互作用的单克隆IgG在诱导凝血酶 - HCII(L444R)复合物解离的能力上模拟了肝素。最后,HCII(L444R)与凝血酶(desPPW)的复合物,其正常结合肝素,但在肝素结合位点和催化位点之间的插入环(“60环”)中缺少Pro60BPro60CTrp60D,在肝素存在下不会解离。这些结果表明,肝素与凝血酶的结合诱导了变构效应,导致凝血酶 - HCII(L444R)复合物不稳定,并且变构效应可能由60环介导。